Quick Answer
Dare Bioscience, Inc. reported Stockholders Equity of $2.84 million for the year ending 2025.
- Dare Bioscience, Inc. showed an increase of +147.3% in Stockholders Equity from 2024 to 2025.
- This data is from Dare Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$97.04 million | Q2 2014: $57.81 million | Q3 2014: $52.53 million | Q1 2015: $40.41 million | Q2 2015: $68.20 million | Q3 2015: $58.64 million | Q1 2016: $35.98 million | Q2 2016: $25.84 million | Q3 2016: $16.62 million | Q1 2017: $7.74 million | Q2 2017: $4.06 million | Q3 2017: $22.43 million | Q1 2018: $15.82 million | Q2 2018: $12.22 million | Q3 2018: $9.58 million | Q1 2019: $3.78 million | Q2 2019: $5.08 million | Q3 2019: $1.81 million | Q1 2020: $3.21 million | Q2 2020: $311.3 thousand | Q3 2020: -$1.39 million | Q1 2021: $3.26 million | Q2 2021: $7.74 million | Q3 2021: $31.89 million | Q1 2022: $30.88 million | Q2 2022: $33.03 million | Q3 2022: $26.34 million | Q1 2023: $4.97 million | Q2 2023: -$2.72 million | Q3 2023: -$2.29 million | Q1 2024: -$11.00 million | Q2 2024: $2.67 million | Q3 2024: -$1.48 million | Q1 2025: -$9.56 million | Q2 2025: -$12.73 million | Q3 2025: $2.86 million.
- Over the full 15 years of available data (2011 to 2025), Dare Bioscience, Inc.'s Stockholders Equity has grown by 104.9%.
- Historical annual values: Fiscal year 2025: $2.84 million | Fiscal year 2024: -$6.01 million | Fiscal year 2023: -$5.05 million | Fiscal year 2022: $11.11 million | Fiscal year 2021: $38.75 million | Fiscal year 2020: -$1.15 million | Fiscal year 2019: $440.8 thousand | Fiscal year 2018: $6.73 million | Fiscal year 2017: $13.29 million | Fiscal year 2016: -$710.6 thousand | Fiscal year 2015: -$46.9 thousand | Fiscal year 2014: $45.33 million | Fiscal year 2013: -$94.30 million | Fiscal year 2012: -$80.04 million | Fiscal year 2011: -$58.40 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: